Evidence map›Paper›PMID 38889755›Full record

ArticleJournal of the National Comprehensive Cancer Network : JNCCN2024

Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer.

Claudia Rosso, Naomie Devico Marciano, Deepika Nathan, Wen-Pin Chen, Christine E McLaren, Kathryn E Osann, Pamela L Flodman, May T Cho, Fa-Chyi Lee, Farshid Dayyani and 2 more

Abstract read
In one paragraph

Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Claudia RossoSchool of Medicine, University of California, Irvine, Irvine, CA.
Naomie Devico MarcianoSchool of Medicine, University of California, Irvine, Irvine, CA.
Deepika NathanDivision of Genetic and Genomic Medicine, Department of Pediatrics, University of California, Irvine, Irvine, CA.
Wen-Pin ChenChao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA.
Christine E McLarenChao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA.
Kathryn E OsannSchool of Medicine, University of California, Irvine, Irvine, CA.
Pamela L FlodmanDivision of Genetic and Genomic Medicine, Department of Pediatrics, University of California, Irvine, Irvine, CA.
May T ChoChao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA.
Fa-Chyi LeeChao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA.
Farshid DayyaniChao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA.
Jason A ZellChao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA.
Jennifer B ValerinChao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA.

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
NCI NIH HHS P30 CA062203
6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year overall survival rate of 10%. In November 2018, NCCN recommended that all patients with PDAC receive genetic counseling (GC) and germline testing regardless of family history. We hypothesized that patients with PDAC were more likely to be referred for testing after this change to the guidelines, regardless of presumed predictive factors, and that compliance would be further improved following the implementation of a hereditary cancer clinic (HCC).

methodsWe conducted a single-institution retrospective analysis of patients diagnosed with PDAC from June 2017 through December 2021 at University of California, Irvine. We compared rates of genetics referral among patients in different diagnostic eras: the 18-month period before the NCCN Guideline change (pre-NCCN era: June 2017 through November 2018), 14 months following the change (post-NCCN era: December 2018 through January 2020), and 18 months after the creation of an HCC (HCC era: June 2020 through December 2021). Family and personal cancer history, genetics referral patterns, and results of GC were recorded. Data were compared using chi-square, Fisher exact, and multivariate analyses.

resultsA total of 335 patients were treated for PDAC (123 pre-NCCN, 109 post-NCCN, and 103 HCC) at University of California, Irvine. Demographics across groups were comparable. Prior to the guideline changes, 30% were referred to GC compared with 54.7% in the post-NCCN era. After the implementation of the HCC, 77.4% were referred to GC (P<.0001). The odds ratio (OR) for referral to GC among patients with a positive family history of cancer progressively decreased following the change (pre-NCCN era: OR, 11.90 [95% CI, 3.00-80.14]; post-NCCN era: OR, 3.39 [95% CI, 1.13-10.76]; HCC era: OR, 3.11 [95% CI, 0.95-10.16]).

conclusionsThe 2018 updates to the NCCN Guidelines for PDAC recommending germline testing for all patients with PDAC significantly increased GC referral rates at our academic medical center. Implementation of an HCC further boosted compliance with guidelines.

Indexed as

Genetic TestingGerm-Line MutationGuideline AdherencePancreatic NeoplasmsAdultAgedCarcinoma, Pancreatic DuctalFemaleGenetic CounselingGenetic Predisposition to DiseaseHumansMaleMiddle AgedPractice Guidelines as TopicReferral and ConsultationRetrospective Studies

Identifiers

PMID38889755
PMCPMC11462954

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.